This web site uses cookies. Do you accept the use of external cookies? Yes No Know more x

Updates on BioMarin clinical development programme

2020-10-26Research
BioMarin shared an update on the 111-209: Phase 2 Study for Children at Risk of Requiring Cervicomedullary Decompression Surgery and the publication of Phase 3 clinical study.

Pfizer starts phase 1 study with Recifercept

2020-10-07Research
Phase 1 Study to Evaluate The Pharmacokinetics, Safety, And Tolerability Of Single Or Multiple Subcutaneous Doses of Recifercept is now active.

Vosoritide phase 3 clinical trial data have been published

2020-09-30Research
Results from the phase 3 clinical trial for vosoritide, that involved children with achondroplasia with ages between 5 to 18 years have been published.

First orphan drug for achondroplasia is validated

2020-08-14Research
The European Medicines Agency (EMA) validated BioMarin's Marketing Authorization Application for Vosoritide to treat Children with Achondroplasia

RIBOMIC starts testing RBM-007 for achondroplasia

2020-07-22Research
RIBOMIC Announced dosing of the first person with RBM-007 in a Phase 1 Clinical Trial for Achondroplasia.

New drug application for achondroplasia by Ribomic

2020-04-23Research
RIBOMIC Announced submission of RBM-007 for Treatment of Achondroplasia
To view this site you need Internet Explorer 8 (or a higher version)
or another internet browser.


Thank You.